Published in Gene Therapy Weekly, January 27th, 2000
The study will use G3139 in combination with paclitaxel (Taxol(R), Bristol Myers Squibb) for the treatment of relapsed small cell lung cancer. About 25% of all lung cancers are the small cell type. While chemotherapy very often produces initial responses, the disease commonly relapses in less than a year. Following relapse, the available treatment options for patients are limited. The study is being conducted under the previously announced Cooperative Research and Development Agreement (CRADA) between Genta and the NCI. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.